Cohen Capital Management Inc. Invests $227,000 in Novo Nordisk A/S (NYSE:NVO)

Cohen Capital Management Inc. purchased a new stake in Novo Nordisk A/S (NYSE:NVO) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 2,642 shares of the company’s stock, valued at approximately $227,000.

Other institutional investors have also bought and sold shares of the company. Indie Asset Partners LLC grew its holdings in shares of Novo Nordisk A/S by 4.2% in the 4th quarter. Indie Asset Partners LLC now owns 3,128 shares of the company’s stock worth $269,000 after purchasing an additional 126 shares during the last quarter. Dividend Assets Capital LLC increased its position in shares of Novo Nordisk A/S by 3.1% during the 4th quarter. Dividend Assets Capital LLC now owns 214,615 shares of the company’s stock worth $18,461,000 after purchasing an additional 6,395 shares in the last quarter. Outfitter Financial LLC lifted its holdings in Novo Nordisk A/S by 9.9% during the 4th quarter. Outfitter Financial LLC now owns 8,795 shares of the company’s stock valued at $757,000 after purchasing an additional 795 shares during the last quarter. Bank of Stockton boosted its position in Novo Nordisk A/S by 6.5% in the fourth quarter. Bank of Stockton now owns 8,151 shares of the company’s stock valued at $701,000 after buying an additional 499 shares in the last quarter. Finally, Arcadia Investment Management Corp MI increased its holdings in shares of Novo Nordisk A/S by 29.8% during the fourth quarter. Arcadia Investment Management Corp MI now owns 4,354 shares of the company’s stock worth $375,000 after buying an additional 1,000 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. BMO Capital Markets cut their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. Finally, StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Trading Up 5.2 %

NVO opened at $88.07 on Friday. Novo Nordisk A/S has a fifty-two week low of $77.82 and a fifty-two week high of $148.15. The company has a market cap of $395.19 billion, a price-to-earnings ratio of 26.77, a price-to-earnings-growth ratio of 0.90 and a beta of 0.45. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The firm has a 50 day simple moving average of $86.01 and a 200 day simple moving average of $108.07.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be given a dividend of $0.7874 per share. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. The ex-dividend date of this dividend is Monday, March 31st. Novo Nordisk A/S’s payout ratio is presently 21.88%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.